TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+14.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.85B
AUM Growth
+$2.85B
(+6.6%)
Cap. Flow
-$35.8M
Cap. Flow
% of AUM
-1.26%
Top 10 Holdings %
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
41
Reduced
45
Closed
16
Top Buys
| 1 |
Thermo Fisher Scientific
TMO
|
$45.7M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$36.7M |
| 3 |
Danaher
DHR
|
$33.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$22.1M |
| 5 |
DexCom
DXCM
|
$20.7M |
Top Sells
| 1 |
Amgen
AMGN
|
$44.1M |
| 2 |
Merck
MRK
|
$40.6M |
| 3 |
Pfizer
PFE
|
$36.5M |
| 4 |
AbbVie
ABBV
|
$27.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 95.34% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $95.8M | 3.37% | 416,560 -191,658 | -32% | -$44.1M |
|
2
Illumina
ILMN
$15.8B
| $95.3M | 3.35% | 257,493 -23,561 | -8% | -$8.72M |
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $86.7M | 3.05% | 179,385 -28,003 | -14% | -$13.5M |
|
4
Johnson & Johnson
JNJ
$427B
| $86.1M | 3.02% | 546,805 | – | – |
|
5
Gilead Sciences
GILD
$140B
| $81.9M | 2.88% | 1,405,371 -238,312 | -14% | -$13.9M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $78.4M | 2.76% | 501,942 +235,151 | +88% | +$36.7M |
|
7
UnitedHealth
UNH
$281B
| $76.9M | 2.7% | 219,185 +33,450 | +18% | +$11.7M |
|
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $72.2M | 2.54% | 305,310 -96,050 | -24% | -$22.7M |
|
|
9
AbbVie
ABBV
$372B
| $66.4M | 2.33% | 619,759 -254,961 | -29% | -$27.3M |
|
10
Medtronic
MDT
$119B
| $62.7M | 2.2% | 534,914 | – | – |
|
11
Bristol-Myers Squibb
BMY
$96B
| $61.4M | 2.16% | 989,908 +44,768 | +5% | +$2.78M |
|
12
Biogen
BIIB
$19.4B
| $60.4M | 2.12% | 246,844 +33,091 | +15% | +$8.1M |
|
|
13
Thermo Fisher Scientific
TMO
$186B
| $59.4M | 2.09% | 127,553 +98,092 | +333% | +$45.7M |
|
|
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
| $51.4M | 1.81% | 293,619 -43,585 | -13% | -$7.63M |
|
|
15
Danaher
DHR
$147B
| $48.8M | 1.72% | 219,840 +152,273 | +225% | +$33.8M |
|
16
Abbott
ABT
$231B
| $47.2M | 1.66% | 431,145 +61,572 | +17% | +$6.74M |
|
|
17
Merck
MRK
$210B
| $45.9M | 1.61% | 560,903 -495,803 | -47% | -$40.6M |
|
18
Eli Lilly
LLY
$657B
| $40.1M | 1.41% | 237,537 +59,900 | +34% | +$10.1M |
|
19
Stryker
SYK
$150B
| $37.6M | 1.32% | 153,330 -4,500 | -3% | -$1.1M |
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $35.2M | 1.24% | 206,487 | – | – |
|
|
HZNP
21
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $34M | 1.2% | 465,016 -138,668 | -23% | -$10.1M |
|
22
Humana
HUM
$36.5B
| $34M | 1.19% | 82,807 -3,200 | -4% | -$1.31M |
|
23
Zimmer Biomet
ZBH
$21B
| $33M | 1.16% | 214,014 +22,077 | +12% | +$3.4M |
|
24
Becton Dickinson
BDX
$55.3B
| $33M | 1.16% | 131,723 | – | – |
|
25
HCA Healthcare
HCA
$94.5B
| $28.8M | 1.01% | 175,097 +93,164 | +114% | +$15.3M |
|